Tributyrin supplement for people with progressive supranuclear palsy, tested through remote visits
Tests the safety and tolerability of tributyrin in people with progressive supranuclear palsy.
Plain-language title generated from the registry record
Registry title: Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Key facts
- Where
- Ann Arbor, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- Domino's FarmsAnn Arbor, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prabesh Kanel
- Trial code
- NCT07863180
- Record updated
- 5 November 2026
- Original description
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.Read full original descriptionShow less
Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
Inclusion: Male or Female, age 45 years and over; Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including; Vertical supranuclear gaze palsy; Repeated unprovoked falls OR tendency to fall on the pull test within 3 years; Access to the internet and webcam for virtual visits; Presence of a caregiver.
Exclusion: Regular use of typical anti-cholinergic drugs; Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer; Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study; Significant metabolic or uncontrolled medical comorbidity; Women of child-bearing potential, or who are pregnant and/or nursing; Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.